

COVID-19 Impact on Global Dolutegravir and Its Combination Drug Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/C3071CA29A6BEN.html>

Date: July 2020

Pages: 99

Price: US\$ 3,900.00 (Single User License)

ID: C3071CA29A6BEN

Abstracts

This report focuses on the global Dolutegravir and Its Combination Drug status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Dolutegravir and Its Combination Drug development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

ViiV Healthcare (GSK)

Adcock Ingram Limited

Aurobindo Pharma

Cipla

Emcure Pharmaceuticals

LAURUS Labs

Mylan

Ranbaxy Pharmaceuticals

Shanghai Desano Pharmaceuticals

JNJ

Market segment by Type, the product can be split into

Dolutegravir

Abacavir/Dolutegravir/Lamivudine

Dolutegravir/Rilpivirine

Market segment by Application, split into

Hospital

Clinic

Drug Center

Other

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Dolutegravir and Its Combination Drug status, future forecast, growth opportunity, key market and key players.

To present the Dolutegravir and Its Combination Drug development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Dolutegravir and Its Combination Drug are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Dolutegravir and Its Combination Drug Revenue

1.4 Market Analysis by Type

1.4.1 Global Dolutegravir and Its Combination Drug Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 Dolutegravir

1.4.3 Abacavir/Dolutegravir/Lamivudine

1.4.4 Dolutegravir/Rilpivirine

1.5 Market by Application

1.5.1 Global Dolutegravir and Its Combination Drug Market Share by Application: 2020 VS 2026

1.5.2 Hospital

1.5.3 Clinic

1.5.4 Drug Center

1.5.5 Other

1.6 Coronavirus Disease 2019 (Covid-19): Dolutegravir and Its Combination Drug Industry Impact

1.6.1 How the Covid-19 is Affecting the Dolutegravir and Its Combination Drug Industry

1.6.1.1 Dolutegravir and Its Combination Drug Business Impact Assessment - Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products

1.6.2 Market Trends and Dolutegravir and Its Combination Drug Potential

Opportunities in the COVID-19 Landscape

1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Dolutegravir and Its Combination Drug Players to Combat Covid-19 Impact

1.7 Study Objectives

1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Dolutegravir and Its Combination Drug Market Perspective (2015-2026)

2.2 Dolutegravir and Its Combination Drug Growth Trends by Regions

2.2.1 Dolutegravir and Its Combination Drug Market Size by Regions: 2015 VS 2020 VS 2026

2.2.2 Dolutegravir and Its Combination Drug Historic Market Share by Regions (2015-2020)

2.2.3 Dolutegravir and Its Combination Drug Forecasted Market Size by Regions (2021-2026)

2.3 Industry Trends and Growth Strategy

2.3.1 Market Top Trends

2.3.2 Market Drivers

2.3.3 Market Challenges

2.3.4 Porter's Five Forces Analysis

2.3.5 Dolutegravir and Its Combination Drug Market Growth Strategy

2.3.6 Primary Interviews with Key Dolutegravir and Its Combination Drug Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Dolutegravir and Its Combination Drug Players by Market Size

3.1.1 Global Top Dolutegravir and Its Combination Drug Players by Revenue (2015-2020)

3.1.2 Global Dolutegravir and Its Combination Drug Revenue Market Share by Players (2015-2020)

3.1.3 Global Dolutegravir and Its Combination Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.2 Global Dolutegravir and Its Combination Drug Market Concentration Ratio

3.2.1 Global Dolutegravir and Its Combination Drug Market Concentration Ratio (CR5 and HHI)

3.2.2 Global Top 10 and Top 5 Companies by Dolutegravir and Its Combination Drug Revenue in 2019

3.3 Dolutegravir and Its Combination Drug Key Players Head office and Area Served

3.4 Key Players Dolutegravir and Its Combination Drug Product Solution and Service

3.5 Date of Enter into Dolutegravir and Its Combination Drug Market

3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Dolutegravir and Its Combination Drug Historic Market Size by Type (2015-2020)

4.2 Global Dolutegravir and Its Combination Drug Forecasted Market Size by Type (2021-2026)

5 DOLUTEGRAVIR AND ITS COMBINATION DRUG BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Dolutegravir and Its Combination Drug Market Size by Application (2015-2020)

5.2 Global Dolutegravir and Its Combination Drug Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Dolutegravir and Its Combination Drug Market Size (2015-2020)

6.2 Dolutegravir and Its Combination Drug Key Players in North America (2019-2020)

6.3 North America Dolutegravir and Its Combination Drug Market Size by Type (2015-2020)

6.4 North America Dolutegravir and Its Combination Drug Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Dolutegravir and Its Combination Drug Market Size (2015-2020)

7.2 Dolutegravir and Its Combination Drug Key Players in Europe (2019-2020)

7.3 Europe Dolutegravir and Its Combination Drug Market Size by Type (2015-2020)

7.4 Europe Dolutegravir and Its Combination Drug Market Size by Application (2015-2020)

8 CHINA

8.1 China Dolutegravir and Its Combination Drug Market Size (2015-2020)

8.2 Dolutegravir and Its Combination Drug Key Players in China (2019-2020)

8.3 China Dolutegravir and Its Combination Drug Market Size by Type (2015-2020)

8.4 China Dolutegravir and Its Combination Drug Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Dolutegravir and Its Combination Drug Market Size (2015-2020)

- 9.2 Dolutegravir and Its Combination Drug Key Players in Japan (2019-2020)
- 9.3 Japan Dolutegravir and Its Combination Drug Market Size by Type (2015-2020)
- 9.4 Japan Dolutegravir and Its Combination Drug Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

- 10.1 Southeast Asia Dolutegravir and Its Combination Drug Market Size (2015-2020)
- 10.2 Dolutegravir and Its Combination Drug Key Players in Southeast Asia (2019-2020)
- 10.3 Southeast Asia Dolutegravir and Its Combination Drug Market Size by Type (2015-2020)
- 10.4 Southeast Asia Dolutegravir and Its Combination Drug Market Size by Application (2015-2020)

11 INDIA

- 11.1 India Dolutegravir and Its Combination Drug Market Size (2015-2020)
- 11.2 Dolutegravir and Its Combination Drug Key Players in India (2019-2020)
- 11.3 India Dolutegravir and Its Combination Drug Market Size by Type (2015-2020)
- 11.4 India Dolutegravir and Its Combination Drug Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

- 12.1 Central & South America Dolutegravir and Its Combination Drug Market Size (2015-2020)
- 12.2 Dolutegravir and Its Combination Drug Key Players in Central & South America (2019-2020)
- 12.3 Central & South America Dolutegravir and Its Combination Drug Market Size by Type (2015-2020)
- 12.4 Central & South America Dolutegravir and Its Combination Drug Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

- 13.1 ViiV Healthcare (GSK)
 - 13.1.1 ViiV Healthcare (GSK) Company Details
 - 13.1.2 ViiV Healthcare (GSK) Business Overview and Its Total Revenue
 - 13.1.3 ViiV Healthcare (GSK) Dolutegravir and Its Combination Drug Introduction

13.1.4 ViiV Healthcare (GSK) Revenue in Dolutegravir and Its Combination Drug Business (2015-2020))

13.1.5 ViiV Healthcare (GSK) Recent Development

13.2 Adcock Ingram Limited

13.2.1 Adcock Ingram Limited Company Details

13.2.2 Adcock Ingram Limited Business Overview and Its Total Revenue

13.2.3 Adcock Ingram Limited Dolutegravir and Its Combination Drug Introduction

13.2.4 Adcock Ingram Limited Revenue in Dolutegravir and Its Combination Drug Business (2015-2020)

13.2.5 Adcock Ingram Limited Recent Development

13.3 Aurobindo Pharma

13.3.1 Aurobindo Pharma Company Details

13.3.2 Aurobindo Pharma Business Overview and Its Total Revenue

13.3.3 Aurobindo Pharma Dolutegravir and Its Combination Drug Introduction

13.3.4 Aurobindo Pharma Revenue in Dolutegravir and Its Combination Drug Business (2015-2020)

13.3.5 Aurobindo Pharma Recent Development

13.4 Cipla

13.4.1 Cipla Company Details

13.4.2 Cipla Business Overview and Its Total Revenue

13.4.3 Cipla Dolutegravir and Its Combination Drug Introduction

13.4.4 Cipla Revenue in Dolutegravir and Its Combination Drug Business (2015-2020)

13.4.5 Cipla Recent Development

13.5 Emcure Pharmaceuticals

13.5.1 Emcure Pharmaceuticals Company Details

13.5.2 Emcure Pharmaceuticals Business Overview and Its Total Revenue

13.5.3 Emcure Pharmaceuticals Dolutegravir and Its Combination Drug Introduction

13.5.4 Emcure Pharmaceuticals Revenue in Dolutegravir and Its Combination Drug Business (2015-2020)

13.5.5 Emcure Pharmaceuticals Recent Development

13.6 LAURUS Labs

13.6.1 LAURUS Labs Company Details

13.6.2 LAURUS Labs Business Overview and Its Total Revenue

13.6.3 LAURUS Labs Dolutegravir and Its Combination Drug Introduction

13.6.4 LAURUS Labs Revenue in Dolutegravir and Its Combination Drug Business (2015-2020)

13.6.5 LAURUS Labs Recent Development

13.7 Mylan

13.7.1 Mylan Company Details

- 13.7.2 Mylan Business Overview and Its Total Revenue
- 13.7.3 Mylan Dolutegravir and Its Combination Drug Introduction
- 13.7.4 Mylan Revenue in Dolutegravir and Its Combination Drug Business (2015-2020)
- 13.7.5 Mylan Recent Development
- 13.8 Ranbaxy Pharmaceuticals
 - 13.8.1 Ranbaxy Pharmaceuticals Company Details
 - 13.8.2 Ranbaxy Pharmaceuticals Business Overview and Its Total Revenue
 - 13.8.3 Ranbaxy Pharmaceuticals Dolutegravir and Its Combination Drug Introduction
 - 13.8.4 Ranbaxy Pharmaceuticals Revenue in Dolutegravir and Its Combination Drug Business (2015-2020)
 - 13.8.5 Ranbaxy Pharmaceuticals Recent Development
- 13.9 Shanghai Desano Pharmaceuticals
 - 13.9.1 Shanghai Desano Pharmaceuticals Company Details
 - 13.9.2 Shanghai Desano Pharmaceuticals Business Overview and Its Total Revenue
 - 13.9.3 Shanghai Desano Pharmaceuticals Dolutegravir and Its Combination Drug Introduction
 - 13.9.4 Shanghai Desano Pharmaceuticals Revenue in Dolutegravir and Its Combination Drug Business (2015-2020)
 - 13.9.5 Shanghai Desano Pharmaceuticals Recent Development
- 13.10 JNJ
 - 13.10.1 JNJ Company Details
 - 13.10.2 JNJ Business Overview and Its Total Revenue
 - 13.10.3 JNJ Dolutegravir and Its Combination Drug Introduction
 - 13.10.4 JNJ Revenue in Dolutegravir and Its Combination Drug Business (2015-2020)
 - 13.10.5 JNJ Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

- 15.1 Research Methodology
 - 15.1.1 Methodology/Research Approach
 - 15.1.2 Data Source
- 15.2 Disclaimer
- 15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Dolutegravir and Its Combination Drug Key Market Segments

Table 2. Key Players Covered: Ranking by Dolutegravir and Its Combination Drug Revenue

Table 3. Ranking of Global Top Dolutegravir and Its Combination Drug Manufacturers by Revenue (US\$ Million) in 2019

Table 4. Global Dolutegravir and Its Combination Drug Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026

Table 5. Key Players of Dolutegravir

Table 6. Key Players of Abacavir/Dolutegravir/Lamivudine

Table 7. Key Players of Dolutegravir/Rilpivirine

Table 8. COVID-19 Impact Global Market: (Four Dolutegravir and Its Combination Drug Market Size Forecast Scenarios)

Table 9. Opportunities and Trends for Dolutegravir and Its Combination Drug Players in the COVID-19 Landscape

Table 10. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 11. Key Regions/Countries Measures against Covid-19 Impact

Table 12. Proposal for Dolutegravir and Its Combination Drug Players to Combat Covid-19 Impact

Table 13. Global Dolutegravir and Its Combination Drug Market Size Growth by Application (US\$ Million): 2020 VS 2026

Table 14. Global Dolutegravir and Its Combination Drug Market Size by Regions (US\$ Million): 2020 VS 2026

Table 15. Global Dolutegravir and Its Combination Drug Market Size by Regions (2015-2020) (US\$ Million)

Table 16. Global Dolutegravir and Its Combination Drug Market Share by Regions (2015-2020)

Table 17. Global Dolutegravir and Its Combination Drug Forecasted Market Size by Regions (2021-2026) (US\$ Million)

Table 18. Global Dolutegravir and Its Combination Drug Market Share by Regions (2021-2026)

Table 19. Market Top Trends

Table 20. Key Drivers: Impact Analysis

Table 21. Key Challenges

Table 22. Dolutegravir and Its Combination Drug Market Growth Strategy

Table 23. Main Points Interviewed from Key Dolutegravir and Its Combination Drug

Players

Table 24. Global Dolutegravir and Its Combination Drug Revenue by Players (2015-2020) (Million US\$)

Table 25. Global Dolutegravir and Its Combination Drug Market Share by Players (2015-2020)

Table 26. Global Top Dolutegravir and Its Combination Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dolutegravir and Its Combination Drug as of 2019)

Table 27. Global Dolutegravir and Its Combination Drug by Players Market Concentration Ratio (CR5 and HHI)

Table 28. Key Players Headquarters and Area Served

Table 29. Key Players Dolutegravir and Its Combination Drug Product Solution and Service

Table 30. Date of Enter into Dolutegravir and Its Combination Drug Market

Table 31. Mergers & Acquisitions, Expansion Plans

Table 32. Global Dolutegravir and Its Combination Drug Market Size by Type (2015-2020) (Million US\$)

Table 33. Global Dolutegravir and Its Combination Drug Market Size Share by Type (2015-2020)

Table 34. Global Dolutegravir and Its Combination Drug Revenue Market Share by Type (2021-2026)

Table 35. Global Dolutegravir and Its Combination Drug Market Size Share by Application (2015-2020)

Table 36. Global Dolutegravir and Its Combination Drug Market Size by Application (2015-2020) (Million US\$)

Table 37. Global Dolutegravir and Its Combination Drug Market Size Share by Application (2021-2026)

Table 38. North America Key Players Dolutegravir and Its Combination Drug Revenue (2019-2020) (Million US\$)

Table 39. North America Key Players Dolutegravir and Its Combination Drug Market Share (2019-2020)

Table 40. North America Dolutegravir and Its Combination Drug Market Size by Type (2015-2020) (Million US\$)

Table 41. North America Dolutegravir and Its Combination Drug Market Share by Type (2015-2020)

Table 42. North America Dolutegravir and Its Combination Drug Market Size by Application (2015-2020) (Million US\$)

Table 43. North America Dolutegravir and Its Combination Drug Market Share by Application (2015-2020)

Table 44. Europe Key Players Dolutegravir and Its Combination Drug Revenue (2019-2020) (Million US\$)

Table 45. Europe Key Players Dolutegravir and Its Combination Drug Market Share (2019-2020)

Table 46. Europe Dolutegravir and Its Combination Drug Market Size by Type (2015-2020) (Million US\$)

Table 47. Europe Dolutegravir and Its Combination Drug Market Share by Type (2015-2020)

Table 48. Europe Dolutegravir and Its Combination Drug Market Size by Application (2015-2020) (Million US\$)

Table 49. Europe Dolutegravir and Its Combination Drug Market Share by Application (2015-2020)

Table 50. China Key Players Dolutegravir and Its Combination Drug Revenue (2019-2020) (Million US\$)

Table 51. China Key Players Dolutegravir and Its Combination Drug Market Share (2019-2020)

Table 52. China Dolutegravir and Its Combination Drug Market Size by Type (2015-2020) (Million US\$)

Table 53. China Dolutegravir and Its Combination Drug Market Share by Type (2015-2020)

Table 54. China Dolutegravir and Its Combination Drug Market Size by Application (2015-2020) (Million US\$)

Table 55. China Dolutegravir and Its Combination Drug Market Share by Application (2015-2020)

Table 56. Japan Key Players Dolutegravir and Its Combination Drug Revenue (2019-2020) (Million US\$)

Table 57. Japan Key Players Dolutegravir and Its Combination Drug Market Share (2019-2020)

Table 58. Japan Dolutegravir and Its Combination Drug Market Size by Type (2015-2020) (Million US\$)

Table 59. Japan Dolutegravir and Its Combination Drug Market Share by Type (2015-2020)

Table 60. Japan Dolutegravir and Its Combination Drug Market Size by Application (2015-2020) (Million US\$)

Table 61. Japan Dolutegravir and Its Combination Drug Market Share by Application (2015-2020)

Table 62. Southeast Asia Key Players Dolutegravir and Its Combination Drug Revenue (2019-2020) (Million US\$)

Table 63. Southeast Asia Key Players Dolutegravir and Its Combination Drug Market

Share (2019-2020)

Table 64. Southeast Asia Dolutegravir and Its Combination Drug Market Size by Type (2015-2020) (Million US\$)

Table 65. Southeast Asia Dolutegravir and Its Combination Drug Market Share by Type (2015-2020)

Table 66. Southeast Asia Dolutegravir and Its Combination Drug Market Size by Application (2015-2020) (Million US\$)

Table 67. Southeast Asia Dolutegravir and Its Combination Drug Market Share by Application (2015-2020)

Table 68. India Key Players Dolutegravir and Its Combination Drug Revenue (2019-2020) (Million US\$)

Table 69. India Key Players Dolutegravir and Its Combination Drug Market Share (2019-2020)

Table 70. India Dolutegravir and Its Combination Drug Market Size by Type (2015-2020) (Million US\$)

Table 71. India Dolutegravir and Its Combination Drug Market Share by Type (2015-2020)

Table 72. India Dolutegravir and Its Combination Drug Market Size by Application (2015-2020) (Million US\$)

Table 73. India Dolutegravir and Its Combination Drug Market Share by Application (2015-2020)

Table 74. Central & South America Key Players Dolutegravir and Its Combination Drug Revenue (2019-2020) (Million US\$)

Table 75. Central & South America Key Players Dolutegravir and Its Combination Drug Market Share (2019-2020)

Table 76. Central & South America Dolutegravir and Its Combination Drug Market Size by Type (2015-2020) (Million US\$)

Table 77. Central & South America Dolutegravir and Its Combination Drug Market Share by Type (2015-2020)

Table 78. Central & South America Dolutegravir and Its Combination Drug Market Size by Application (2015-2020) (Million US\$)

Table 79. Central & South America Dolutegravir and Its Combination Drug Market Share by Application (2015-2020)

Table 80. ViiV Healthcare (GSK) Company Details

Table 81. ViiV Healthcare (GSK) Business Overview

Table 82. ViiV Healthcare (GSK) Product

Table 83. ViiV Healthcare (GSK) Revenue in Dolutegravir and Its Combination Drug Business (2015-2020) (Million US\$)

Table 84. ViiV Healthcare (GSK) Recent Development

- Table 85. Adcock Ingram Limited Company Details
- Table 86. Adcock Ingram Limited Business Overview
- Table 87. Adcock Ingram Limited Product
- Table 88. Adcock Ingram Limited Revenue in Dolutegravir and Its Combination Drug Business (2015-2020) (Million US\$)
- Table 89. Adcock Ingram Limited Recent Development
- Table 90. Aurobindo Pharma Company Details
- Table 91. Aurobindo Pharma Business Overview
- Table 92. Aurobindo Pharma Product
- Table 93. Aurobindo Pharma Revenue in Dolutegravir and Its Combination Drug Business (2015-2020) (Million US\$)
- Table 94. Aurobindo Pharma Recent Development
- Table 95. Cipla Company Details
- Table 96. Cipla Business Overview
- Table 97. Cipla Product
- Table 98. Cipla Revenue in Dolutegravir and Its Combination Drug Business (2015-2020) (Million US\$)
- Table 99. Cipla Recent Development
- Table 100. Emcure Pharmaceuticals Company Details
- Table 101. Emcure Pharmaceuticals Business Overview
- Table 102. Emcure Pharmaceuticals Product
- Table 103. Emcure Pharmaceuticals Revenue in Dolutegravir and Its Combination Drug Business (2015-2020) (Million US\$)
- Table 104. Emcure Pharmaceuticals Recent Development
- Table 105. LAURUS Labs Company Details
- Table 106. LAURUS Labs Business Overview
- Table 107. LAURUS Labs Product
- Table 108. LAURUS Labs Revenue in Dolutegravir and Its Combination Drug Business (2015-2020) (Million US\$)
- Table 109. LAURUS Labs Recent Development
- Table 110. Mylan Company Details
- Table 111. Mylan Business Overview
- Table 112. Mylan Product
- Table 113. Mylan Revenue in Dolutegravir and Its Combination Drug Business (2015-2020) (Million US\$)
- Table 114. Mylan Recent Development
- Table 115. Ranbaxy Pharmaceuticals Business Overview
- Table 116. Ranbaxy Pharmaceuticals Product
- Table 117. Ranbaxy Pharmaceuticals Company Details

Table 118. Ranbaxy Pharmaceuticals Revenue in Dolutegravir and Its Combination Drug Business (2015-2020) (Million US\$)

Table 119. Ranbaxy Pharmaceuticals Recent Development

Table 120. Shanghai Desano Pharmaceuticals Company Details

Table 121. Shanghai Desano Pharmaceuticals Business Overview

Table 122. Shanghai Desano Pharmaceuticals Product

Table 123. Shanghai Desano Pharmaceuticals Revenue in Dolutegravir and Its Combination Drug Business (2015-2020) (Million US\$)

Table 124. Shanghai Desano Pharmaceuticals Recent Development

Table 125. JNJ Company Details

Table 126. JNJ Business Overview

Table 127. JNJ Product

Table 128. JNJ Revenue in Dolutegravir and Its Combination Drug Business (2015-2020) (Million US\$)

Table 129. JNJ Recent Development

Table 130. Research Programs/Design for This Report

Table 131. Key Data Information from Secondary Sources

Table 132. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Dolutegravir and Its Combination Drug Market Share by Type: 2020 VS 2026

Figure 2. Dolutegravir Features

Figure 3. Abacavir/Dolutegravir/Lamivudine Features

Figure 4. Dolutegravir/Rilpivirine Features

Figure 5. Global Dolutegravir and Its Combination Drug Market Share by Application: 2020 VS 2026

Figure 6. Hospital Case Studies

Figure 7. Clinic Case Studies

Figure 8. Drug Center Case Studies

Figure 9. Other Case Studies

Figure 10. Dolutegravir and Its Combination Drug Report Years Considered

Figure 11. Global Dolutegravir and Its Combination Drug Market Size YoY Growth 2015-2026 (US\$ Million)

Figure 12. Global Dolutegravir and Its Combination Drug Market Share by Regions: 2020 VS 2026

Figure 13. Global Dolutegravir and Its Combination Drug Market Share by Regions (2021-2026)

Figure 14. Porter's Five Forces Analysis

Figure 15. Global Dolutegravir and Its Combination Drug Market Share by Players in 2019

Figure 16. Global Top Dolutegravir and Its Combination Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dolutegravir and Its Combination Drug as of 2019)

Figure 17. The Top 10 and 5 Players Market Share by Dolutegravir and Its Combination Drug Revenue in 2019

Figure 18. North America Dolutegravir and Its Combination Drug Market Size YoY Growth (2015-2020) (Million US\$)

Figure 19. Europe Dolutegravir and Its Combination Drug Market Size YoY Growth (2015-2020) (Million US\$)

Figure 20. China Dolutegravir and Its Combination Drug Market Size YoY Growth (2015-2020) (Million US\$)

Figure 21. Japan Dolutegravir and Its Combination Drug Market Size YoY Growth (2015-2020) (Million US\$)

Figure 22. Southeast Asia Dolutegravir and Its Combination Drug Market Size YoY

Growth (2015-2020) (Million US\$)

Figure 23. India Dolutegravir and Its Combination Drug Market Size YoY Growth (2015-2020) (Million US\$)

Figure 24. Central & South America Dolutegravir and Its Combination Drug Market Size YoY Growth (2015-2020) (Million US\$)

Figure 25. ViiV Healthcare (GSK) Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 26. ViiV Healthcare (GSK) Revenue Growth Rate in Dolutegravir and Its Combination Drug Business (2015-2020)

Figure 27. Adcock Ingram Limited Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 28. Adcock Ingram Limited Revenue Growth Rate in Dolutegravir and Its Combination Drug Business (2015-2020)

Figure 29. Aurobindo Pharma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 30. Aurobindo Pharma Revenue Growth Rate in Dolutegravir and Its Combination Drug Business (2015-2020)

Figure 31. Cipla Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 32. Cipla Revenue Growth Rate in Dolutegravir and Its Combination Drug Business (2015-2020)

Figure 33. Emcure Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 34. Emcure Pharmaceuticals Revenue Growth Rate in Dolutegravir and Its Combination Drug Business (2015-2020)

Figure 35. LAURUS Labs Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 36. LAURUS Labs Revenue Growth Rate in Dolutegravir and Its Combination Drug Business (2015-2020)

Figure 37. Mylan Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 38. Mylan Revenue Growth Rate in Dolutegravir and Its Combination Drug Business (2015-2020)

Figure 39. Ranbaxy Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 40. Ranbaxy Pharmaceuticals Revenue Growth Rate in Dolutegravir and Its Combination Drug Business (2015-2020)

Figure 41. Shanghai Desano Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 42. Shanghai Desano Pharmaceuticals Revenue Growth Rate in Dolutegravir and Its Combination Drug Business (2015-2020)

Figure 43. JNJ Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 44. JNJ Revenue Growth Rate in Dolutegravir and Its Combination Drug Business (2015-2020)

Business (2015-2020)

Figure 45. Bottom-up and Top-down Approaches for This Report

Figure 46. Data Triangulation

Figure 47. Key Executives Interviewed

I would like to order

Product name: COVID-19 Impact on Global Dolutegravir and Its Combination Drug Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/C3071CA29A6BEN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C3071CA29A6BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

